Literature DB >> 18720772

Ultrasonographic evaluation of normal canine iliopsoas muscle.

Matthew S Cannon1, Sarah M Puchalski.   

Abstract

The aim of this study was to describe the normal ultrasonographic appearance of the iliopsoas muscle and related landmarks. Hind limbs of five dog cadavers with no history of lameness were evaluated. The origin and mid-body of the psoas major and the common insertion of the iliacus and psoas major on the lesser trochanter of the femur were identified and evaluated. New methylene blue was injected under ultrasonographic guidance at the three sites. Dissection was performed to confirm placement of the dye. The L3 origin, mid-body, and insertion of the muscle were identified in all dogs and were consistent in appearance and compatible with the general appearance of muscle and tendons. The L2 origin was consistently difficult to image. The same ultrasound technique was subsequently applied to four healthy dogs, and consistent images of the iliopsoas muscle and associated landmarks were obtained. In this study, the major structures of the iliopsoas could be identified and in all dogs had a similar appearance. Ultrasound is an important tool for the diagnosis of musculotendinous injury and may be useful for identification of ilipsoas injury as a cause of lameness in the dog.

Entities:  

Mesh:

Year:  2008        PMID: 18720772     DOI: 10.1111/j.1740-8261.2008.00385.x

Source DB:  PubMed          Journal:  Vet Radiol Ultrasound        ISSN: 1058-8183            Impact factor:   1.363


  2 in total

1.  Observational Study on Lameness Recovery in 10 Dogs Affected by Iliopsoas Injury and Submitted to a Physiotherapeutic Approach.

Authors:  Giuseppe Spinella; Benedetta Davoli; Vincenzo Musella; Ludovica Dragone
Journal:  Animals (Basel)       Date:  2021-02-06       Impact factor: 2.752

2.  Viscoelastic response (VisR) imaging for assessment of viscoelasticity in Voigt materials.

Authors:  Mallory R Selzo; Caterina M Gallippi
Journal:  IEEE Trans Ultrason Ferroelectr Freq Control       Date:  2013-12       Impact factor: 2.725

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.